developed the first dual VEGFR/PARP inhibitor, which inhibits angiogenesis and invasion by negatively regulating the expression of VEGFR and PARP, thereby suppressing the growth and metastasis of BRCA wild-type breast cancer (118). Here, KDR is linked to breast cancer.